Prognostic value of genetic alterations and 18F-FDG PET/CT imaging features in diffuse large B cell lymphoma.
Diffuse large B-cell lymphoma (DLBCL) is the leading type of non-Hodgkin lymphoma (NHL) in the West, with standard therapy R-CHOP being ineffective for about one-third of patients, highlighting the need for early identification for alternative treatments. While R-CHOP cures 50%-70% of DLBCL patients, its limitations and the traditional International Prognostic Index (IPI) necessitate refined predictors. Molecular aberrations in tumor cells and emerging radiomics provide significant prognostic insights. Our study demonstrates that combining genomic data with imaging features and clinical data optimally predicts response to R-CHOP in DLBCL patients (AUC = 0.904, balanced accuracy of 80%), identifying BCL6 gene amplification as a key genetic marker.
Integrating clinical, imaging, and genomic features, this holistic approach enhances predictive accuracy, refines patient selection, and guides toward alternative therapeutic avenues, ensuring tailored, potentially life-saving treatments.
Ferrer-Lores B, Lozano J, Fuster-Matanzo A, Mayorga-Ruiz I, Moreno-Ruiz P, Bellvís F, Teruel AB, Saus A, Ortiz A, Villamón-Ribate E, Serrano-Alcalá A, Piñana JL, Sopena P, Dosdá R, Solano C, Alberich-Bayarri Á, Terol MJ. Prognostic value of genetic alterations and 18F-FDG PET/CT imaging features in diffuse large B cell lymphoma. Am J Cancer Res. 2023 Feb 15;13(2):509-525